Administrating of FGF21 analogs and mimetics has demonstrated therapeutic benefit in human and rodent models of metabolic diseases, but still more studies and clinical trials will be required to prove the efficacy of these treatments. This evidence concerns the gene FGF21 and metabolic disease.